Literature DB >> 8380569

Potential improvement of three dimension treatment planning and proton beams in fractionated radiotherapy of large cerebral arteriovenous malformations.

R Miralbell1, M Urie.   

Abstract

The treatment of large cerebral arteriovenous malformations is a surgical challenge, especially for deep seated brain locations. Furthermore, these lesions are unfit for radiosurgical approaches due to a high risk of complications secondary to high radiation doses to large brain volumes. Fractionated precision radiotherapy can potentially deliver high, uniform, target-contoured dose distributions optimizing the dose reduction to the critical surrounding brain. The results of a study are presented in such a way that dose distributions achievable with proton beams are compared to those with 10 MV x-rays; and the potential improvements with protons evaluated, relying heavily on dose-volume histograms to examine the coverage of the lesion as well as the dose to the normal brain, brain-stem, and optic chiasm.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380569     DOI: 10.1016/0360-3016(93)90360-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

Review 1.  Uses of 3D planning in addition to creating a good treatment: ongoing studies at MGH/HCL.

Authors:  M M Urie
Journal:  Radiat Environ Biophys       Date:  1992       Impact factor: 1.925

Review 2.  Treatment planning with heavy ions.

Authors:  P Chauvel
Journal:  Radiat Environ Biophys       Date:  1995-03       Impact factor: 1.925

3.  Assessment of organ dose reduction and secondary cancer risk associated with the use of proton beam therapy and intensity modulated radiation therapy in treatment of neuroblastomas.

Authors:  Hiroshi Fuji; Uwe Schneider; Yuji Ishida; Masahiro Konno; Haruo Yamashita; Yuki Kase; Shigeyuki Murayama; Tsuyoshi Onoe; Hirofumi Ogawa; Hideyuki Harada; Hirofumi Asakura; Tetsuo Nishimura
Journal:  Radiat Oncol       Date:  2013-11-01       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.